Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

1.4K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.4K
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

1.6K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.6K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

1.4K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.4K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autism in neurofibromatosis type 1: prevalence, phenotype and clinical implications.

Molecular autism·2026
Same author

A double-blind randomized controlled trial of personalized upper-alpha neurofeedback in children with ADHD.

Journal of child psychology and psychiatry, and allied disciplines·2026
Same author

Personality Functioning and Antisociality of Youth Accessing Residential Substance Use Withdrawal in Australia.

Drug and alcohol review·2026
Same author

Electroconvulsive treatment for schizophrenia: decade of national Scottish data.

BJPsych bulletin·2026
Same author

A large dataset of brain imaging linked to health systems data: curation and access to a whole system national cohort from NHS Scotland.

GigaScience·2026
Same author

Predicting future dementia from routine clinical MRI and linked healthcare data.

Alzheimer's research & therapy·2026
Same journal

Caution in interpreting value-related change after psilocybin: Comment on Kerr-Gaffney et al. (2026).

Journal of psychopharmacology (Oxford, England)·2026
Same journal

Effects of antidepressants, anesthetics and sedatives/hypnotics on sleep-associated memory consolidation - A systematic review.

Journal of psychopharmacology (Oxford, England)·2026
Same journal

Mental resilience is not meaningfully associated with the frequency and severity of alcohol hangover.

Journal of psychopharmacology (Oxford, England)·2026
Same journal

Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex.

Journal of psychopharmacology (Oxford, England)·2026
Same journal

Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis.

Journal of psychopharmacology (Oxford, England)·2026
Same journal

The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review.

Journal of psychopharmacology (Oxford, England)·2026
See all related articles

Related Experiment Video

Updated: Apr 23, 2026

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

16.7K

Predicting methylphenidate response in attention deficit hyperactivity disorder: a preliminary study.

Blair A Johnston1, David Coghill2, Keith Matthews2

  • 1Division of Neuroscience, Medical Research Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK blair.a.johnston@gmail.com.

Journal of Psychopharmacology (Oxford, England)
|September 20, 2014
PubMed
Summary
This summary is machine-generated.

Predicting attention deficit hyperactivity disorder (ADHD) medication response is challenging. This study used neuropsychological measures to predict methylphenidate (MPH) response in ADHD boys with 77% accuracy.

Keywords:
ADHDattention deficit hyperactivity disorderchildrenconduct disorderdrug activitydrug sensitivitymethylphenidatepattern recognitionpredictive methodstherapeutic drugs

More Related Videos

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

5.4K
Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
13:09

Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol

Published on: April 1, 2018

9.7K

Related Experiment Videos

Last Updated: Apr 23, 2026

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

16.7K
The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

5.4K
Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
13:09

Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol

Published on: April 1, 2018

9.7K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pediatrics

Background:

  • Methylphenidate (MPH) is a primary pharmacological treatment for attention deficit hyperactivity disorder (ADHD).
  • Current methods for predicting MPH response are limited, often relying on empirical trials.
  • Individual variability in patient response and adverse effects necessitates predictive tools.

Purpose of the Study:

  • To investigate the potential of sociodemographic, clinical, and neuropsychological measures to predict individual clinical response to MPH in boys with ADHD.
  • To develop a predictive model for MPH response as a proof-of-concept.

Main Methods:

  • A multivariate analysis approach was applied to data from 43 boys diagnosed with ADHD.
  • Participants were classified as MPH responders (n=30) or non-responders (n=13).
  • Predictive variables included sociodemographic, clinical, and neuropsychological assessments, notably a 'go/no go' task and comorbid conduct disorder.

Main Results:

  • The multivariate predictive model achieved an accuracy of 77% (p = 0.005) in distinguishing MPH responders from non-responders.
  • Performance on the 'go/no go' task and the presence of comorbid conduct disorder were the most significant predictors.
  • No significant differences in age or verbal intelligence quotient (IQ) were found between responders and non-responders.

Conclusions:

  • This preliminary study demonstrates the potential for a neuropsychological-based approach to predict MPH response in ADHD.
  • The findings suggest that predictive models can help minimize unnecessary exposure to MPH and its potential adverse effects.
  • Further investigation is warranted to validate and refine this predictive method for clinical application.